Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

JS006

Catalog No. T9901A-1766 Copy Product Info
🥰Excellent
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. It is applicable in the study of advanced and/or metastatic cancers, such as non-small cell lung cancer (NSCLC), advanced lymphoma, and advanced/metastatic triple-negative breast cancer (TNBC), particularly when resistance to PD-1/PD-L1 inhibitors has developed.

JS006

Copy Product Info
🥰Excellent
Catalog No. T9901A-1766

JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. It is applicable in the study of advanced and/or metastatic cancers, such as non-small cell lung cancer (NSCLC), advanced lymphoma, and advanced/metastatic triple-negative breast cancer (TNBC), particularly when resistance to PD-1/PD-L1 inhibitors has developed.

JS006
Pack SizePriceUSA StockGlobal StockQuantity
1 mgInquiryInquiryInquiry
5 mgInquiryInquiryInquiry
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. It is applicable in the study of advanced and/or metastatic cancers, such as non-small cell lung cancer (NSCLC), advanced lymphoma, and advanced/metastatic triple-negative breast cancer (TNBC), particularly when resistance to PD-1/PD-L1 inhibitors has developed.
Chemical Properties
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy JS006 | purchase JS006 | JS006 cost | order JS006